利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.021 秒)

    Chemokine mutants in the treatment of multiple sclerosis
    1.
    发明授权
    Chemokine mutants in the treatment of multiple sclerosis 失效
    趋化因子突变体治疗多发性硬化症

    公开(公告)号：US07402303B2

    公开(公告)日：2008-07-22

    申请号：US10398457

    申请日：2001-10-03

    申请人： Amanda Proudfoot ,  Timothy N. C. Wells ,  Marie Kosco-Vilbois

    发明人： Amanda Proudfoot ,  Timothy N. C. Wells ,  Marie Kosco-Vilbois

    IPC分类号： A61K45/00 ,  C12P21/00

    CPC分类号： C07K14/523 ,  A61K38/00

    摘要： Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.

    摘要翻译： CC趋化因子的突变体，其在40个环的阳离子位点含有至少两个突变，相对于野生型分子具有降低的GAG结合活性。 特别地已经发现，这种突变趋化因子在多发性硬化症和/或脱髓鞘疾病的治疗中是有效的。 RANTES的三重突变体是显示最好结果的化合物。

    Chemokine receptor antagonist and cyclosporin in combined therapy
    2.
    发明授权
    Chemokine receptor antagonist and cyclosporin in combined therapy 失效
    趋化因子受体拮抗剂和环孢菌素联合治疗

    公开(公告)号：US06902728B1

    公开(公告)日：2005-06-07

    申请号：US09787335

    申请日：1999-09-16

    申请人： Hermann-Joseph Grone ,  Peter J. Nelson ,  Amanda Proudfoot ,  Timothy N. C. Wells

    发明人： Hermann-Joseph Grone ,  Peter J. Nelson ,  Amanda Proudfoot ,  Timothy N. C. Wells

    IPC分类号： A61K45/00 ,  A61K20060101 ,  A61K38/00 ,  A61K38/13 ,  A61K38/19 ,  A61P37/06 ,  C07K14/52

    CPC分类号： C07K14/521 ,  Y10S514/885

    摘要： The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.

    摘要翻译： 本文公开了将趋化因子受体拮抗剂与环孢菌素一起用于产生用于治疗或预防移植器官，组织或细胞排斥的药物组合物。 用于同时，分离或顺序使用其用于上述指定治疗的活性成分的所述药物组合物也被公开和要求保护。 特别地，实验上显示使用Met-RANTES与环孢菌素A一起制备用于治疗肾同种异体移植排斥的药物组合物。

    Uses of a chemokine receptor able to bind to MCP-1, MIP-1α and/or RANTES
    5.
    发明授权
    Uses of a chemokine receptor able to bind to MCP-1, MIP-1α and/or RANTES 失效
    使用能够结合MCP-1，MIP-1α和/或RANTES的趋化因子受体

    公开(公告)号：US07655425B2

    公开(公告)日：2010-02-02

    申请号：US10933356

    申请日：2004-09-03

    申请人： Timothy N. C. Wells ,  Christine A. Power

    发明人： Timothy N. C. Wells ,  Christine A. Power

    IPC分类号： G01N33/567 ,  A61K39/395 ,  C07K14/715

    CPC分类号： C07K14/7158

    摘要： A chemokine receptor binds to MCP-1, MIP-1α and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1α and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.

    摘要翻译： 趋化因子受体结合MCP-1，MIP-1α和/或RANTES。 它可用于筛选作为MCP-1，MIP-1α和/或RANTES拮抗剂的药剂。 这样的药剂可用于治疗各种疾病，包括过敏，动脉粥样化和由病毒介导的疾病。 它们也可用于预防移植物排斥和保护干细胞免受化学疗法的潜在破坏性影响。

    Chemokine receptor able to bind to MCP-1, MIP-1 α and/or rantes and its uses
    6.
    发明授权
    Chemokine receptor able to bind to MCP-1, MIP-1 α and/or rantes and its uses 失效
    能够结合MCP-1，MIP-1α和/或细胞的趋化因子受体及其用途

    公开(公告)号：US07183063B2

    公开(公告)日：2007-02-27

    申请号：US10120394

    申请日：2002-04-12

    申请人： Timothy N. C. Wells ,  Christine A. Power

    发明人： Timothy N. C. Wells ,  Christine A. Power

    IPC分类号： G01N33/53 ,  G01N33/567

    CPC分类号： C07K14/7158

    摘要： A chemokine receptor binds to MCP-1, MIP-1α and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1α and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.

    摘要翻译： 趋化因子受体结合MCP-1，MIP-1α和/或RANTES。 它可用于筛选作为MCP-1，MIP-1α和/或RANTES拮抗剂的药剂。 这样的药剂可用于治疗各种疾病，包括过敏，动脉粥样化和由病毒介导的疾病。 它们也可用于预防移植物排斥和保护干细胞免受化学疗法的潜在破坏性影响。